TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer von Oxnard, G.R., Yang, J.C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K.S., Frigault, M.M., Vishwanathan, K., Ghiorghiu, D., Ramalingam, S.S., Ahn, M.-J.

Volltext

135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC von Oxnard, G R, Thress, K S, Alden, R S, Lawrance, R, Paweletz, C P, Cantarini, M, Barrett, C, Yang, J, Jänne, P

Volltext

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity von Ballard, Peter, Yates, James W T, Yang, Zhenfan, Kim, Dong-Wan, Yang, James Chih-Hsin, Cantarini, Mireille, Pickup, Kathryn, Jordan, Angela, Hickey, Mike, Grist, Matthew, Box, Matthew, Johnström, Peter, Varnäs, Katarina, Malmquist, Jonas, Thress, Kenneth S, Jänne, Pasi A, Cross, Darren

Volltext

Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC: 135O_PR von Oxnard, G R, Thress, K S, Alden, R S, Lawrance, R, Paweletz, C P, Cantarini, M, Barrett, C, Yang, J, Jänne, P

Volltext

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overal... von Mok, Tony S K, Kim, Sang-We, Wu, Yi-Long, Nakagawa, Kazuhiko, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Shi, Xiaojin, Rukazenkov, Yuri, Haddad, Vincent, Thress, Kenneth S, Soria, Jean-Charles

Volltext

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial von Thress, Kenneth S., Jacobs, Vivien, Angell, Helen K., Yang, James Chih-Hsin, Sequist, Lecia V., Blackhall, Fiona, Su, Wu-Chou, Schuler, Martin, Wolf, Jürgen, Gold, Kathryn A., Cantarini, Mireille, Barrett, J. Carl, Jänne, Pasi A.

Volltext

The Presence of Circulating Tumor DNA in Ovarian Cancer Patients After Platinum-Based Chemotherapy von Eakin, C., Sun, K., Shan, M., Zhou, Y., Feng, B., Wang, S., Posey, J., Rubio, M., Garg, K., Thress, K.S., Wang, J., Monk, B.J.

Volltext

Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation von Clurman, B E, Sheaff, R J, Thress, K, Groudine, M, Roberts, J M

Volltext

Reaper-induced dissociation of a Scythe-sequestered cytochrome c-releasing activity von Thress, K, Evans, E.K, Kornbluth, S

Volltext

OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms von Oxnard, G., Hu, Y., Mileham, K., Tracy, P., Feeney, N., Sholl, L., Paweletz, C., Thress, K., Jänne, P.

Volltext

P3.01-074 Genomic Analysis of Tumor and Plasma in T790M Mutant Positive EGFR Lung Cancer Patients before and after Osimertinib Treatment von Yang, J.C., Yu, C., Shih, J., Ho, C., Liao, W., Lee, J., Tsai, T., Su, K., Shih, M., Chang, Y.L., Bai, Y., Huang, D., Thress, K., Lin, C.

Volltext

Scythe: a novel reaper-binding apoptotic regulator von Thress, Kenneth, Henzel, William, Shillinglaw, Wendy, Kornbluth, Sally

Volltext

OA 10.01 Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays von Ahn, M., Han, J., Tsai, C., Delmonte, A., Hsia, T., Laskin, J., Kim, S., He, Y., Hida, T., Maemondo, M., Kato, T., Jenkins, S., Markovets, A., Thress, K., Mok, T.

Volltext

A family of ubiquitin-like proteins binds the ATPase domain of Hsp70-like Stch von Kaye, Frederic J., Modi, Sanjay, Ivanovska, Irena, Koonin, Eugene V., Thress, Kenneth, Kubo, Akihito, Kornbluth, Sally, Rose, Mark D.

Volltext

P2.02-052 A Clinically-Validated Universal Companion Diagnostic Platform for Cancer Patient Care von Sun, J., Li, Y., Milbury, C., Skoletsky, J., Burns, C., Yip, W., Luo, J., Dewal, N., Johnson, A., Gowen, K., Tong, J., He, Y., He, J., White, J., Roels, S., Tsuji, A., Truesdell, J., Peters, E., Gilbert, H., Wu, C., Schleifman, E., Barrett, C., Thress, K., Jenkins, S., Elvin, J., Otto, G., Lipson, D., Ross, J., Miller, V., Stephens, P.J., Doherty, M., Vietz, C.

Volltext

P3.02-062 An EGFR Follow-On Companion Diagnostic for Clinical Care of Patients with NSCLC von Li, Y., Luo, J., Yip, W., Skoletsky, J., Milbury, C., Burns, C., Tsuji, A., Truesdell, J., Peters, E., Gilbert, H., Wu, C., Schleifman, E., Barrett, C., Thress, K., Jenkins, S., Elvin, J., Otto, G., Lipson, D., Ross, J., Miller, V., Stephens, P.J., Doherty, M., Vietz, C., Sun, J.

Volltext

Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper von Thress, Kenneth, Song, Jaewhan, Morimoto, Richard I., Kornbluth, Sally

Volltext

1270PLEVELS OF EGFR T790M IN PLASMA DNA AS A PREDICTIVE BIOMARKER FOR RESPONSE TO AZD9291, A MUTANT-SELECTIVE EGFR KINASE INHIBITOR von Thress, K., Yang, J.C., Ahn, M., Kim, D., Kim, S., Ohe, Y., Planchard, D., Brant, R., Carr, H., Dearden, S., Jenkins, S., Cantarini, M., Ghiorghiu, S., Barrett, J.C., Janne, P.A., Oxnard, G.R.

Volltext

Levels of Egfr T790M in Plasma Dna As a Predictive Biomarker for Response to Azd9291, a Mutant-Selective Egfr Kinase Inhibitor von Thress, K., Yang, J.C., Ahn, M., Kim, D., Kim, S., Ohe, Y., Planchard, D., Brant, R., Carr, H., Dearden, S., Jenkins, S., Cantarini, M., Ghiorghiu, S., Barrett, J.C., Janne, P.A., Oxnard, G.R.

Volltext

Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain Metastases von Ballard, P, Yang, P, Cross, D, Yates, J, Finlay, MRV, Grist, M, Box, M, Johnstrom, P, Varnas, K, Malmquist, J, Halldin, C, Farde, L, Thress, K

Volltext